盟科药业(688373) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥17,276,928.37, representing a year-on-year increase of 61.66%[6] - The net profit attributable to shareholders was -¥56,162,215.81, with a net profit excluding non-recurring gains and losses of -¥66,094,526.04[6] - Basic and diluted earnings per share were both -¥0.09[7] - Net profit for Q1 2023 was a loss of ¥56,162,215.81, compared to a loss of ¥51,037,472.73 in Q1 2022, indicating a deterioration in profitability[21] - The company reported a total comprehensive loss of ¥60,536,884.08 for Q1 2023, compared to a loss of ¥51,142,420.56 in Q1 2022[22] Cash Flow - The net cash flow from operating activities was -¥52,110,741.31[6] - Cash flow from operating activities showed a net outflow of ¥52,110,741.31 in Q1 2023, an improvement from a net outflow of ¥59,596,616.66 in Q1 2022[24] - Cash inflow from investment activities was ¥1,007,024,951.62 in Q1 2023, significantly higher than ¥367,679,389.19 in Q1 2022[24] - Cash outflow from investment activities totaled ¥936,466,469.01 in Q1 2023, compared to ¥310,864,930.21 in Q1 2022, reflecting increased investment activity[24] - Cash flow from financing activities resulted in a net outflow of ¥8,706,496.12 in Q1 2023, worsening from a net outflow of ¥2,407,742.71 in Q1 2022[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,434,639,407.35, down 4.19% from the end of the previous year[7] - As of March 31, 2023, the total current assets amounted to CNY 1,309,827,148.68, a decrease of 4.9% from CNY 1,370,505,453.28 at the end of 2022[16] - The total liabilities decreased to CNY 273,041,997.26 from CNY 283,095,971.09, indicating a reduction of 3.7%[17] - The company's total equity decreased to CNY 1,161,597,410.09 from CNY 1,214,274,089.45, a decline of 4.3%[17] - The company's short-term borrowings were reported at CNY 48,752,200.00, which is a new entry in the current liabilities section[17] Research and Development - Total R&D investment amounted to ¥43,468,902.65, an increase of 32.06% compared to the previous year[7] - R&D investment accounted for 251.60% of operating revenue, a decrease of 56.40 percentage points[7] - The company increased its academic promotion efforts, which contributed to the rapid growth in revenue[10] Inventory and Receivables - The company's inventory increased significantly to CNY 32,114,012.87 from CNY 21,888,500.05, marking an increase of 46.5%[16] - The total receivables decreased slightly to CNY 10,747,847.78 from CNY 11,102,134.08, a decline of 3.2%[14] Non-Recurring Items - The company reported a non-recurring gain of ¥9,932,310.23 during the period[9]